Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide

Clinical Cancer Research

Volumn 19, Issue 6, 2013, Pages 1458-1466

  Zimmerman, Eric I ^a   Hu, Shuiying ^a   Roberts, Justin L ^a   Gibson, Alice A ^a   Orwick, Shelley J ^a   Li, Lie ^a   Sparreboom, Alex ^a   Baker, Sharyn D ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CRIZOTINIB; DASATINIB; DRUG METABOLITE; GEFITINIB; IMATINIB; NILOTINIB; OATP1B1 PROTEIN; OATP1B2 PROTEIN; OATP1B3 PROTEIN; PAZOPANIB; SORAFENIB; SORAFENIB GLUCURONIDE; SORAFENIB N OXIDE; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VEMURAFENIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTIFICIAL MEMBRANE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG TRANSPORT; EX VIVO STUDY; FEMALE; GENE SILENCING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTESTINE; LIVER METABOLISM; LIVER MICROSOME; MICROSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ANIMALS; ANTINEOPLASTIC AGENTS; GLUCURONIC ACID; HEK293 CELLS; HUMANS; MICE; MICE, TRANSGENIC; NEOPLASMS; NIACINAMIDE; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; PHENYLUREA COMPOUNDS;

EID: 84875201565     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3306     Document Type: Article

References (32)

1. Caraglia M, Santini D, Bronte G, Rizzo S, Sortino G, Rini GB, et al. Predicting efficacy and toxicity in the era of targeted therapy: focus on anti-EGFR and anti-VEGF molecules. Curr Drug Metab 2011;12: 944-55.
2. Humphrey RW, Brockway-Lunardi LM, Bonk DT, Dohoney KM, Doroshow JH, Meech SJ, et al. Opportunities and challenges in the development of experimental drug combinations for cancer. J Natl Cancer Inst 2011;103:1222-6.
3. Di Gion P, Kanefendt F, Lindauer A, Scheffler M, Doroshyenko O, Fuhr U, et al. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet 2011; 50:551-603.
4. Scheffler M, Di Gion P, Doroshyenko O, Wolf J, Fuhr U. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines. Clin Pharmacokinet 2011;50:371-403.
5. Baker SD, Hu S. Pharmacokinetic considerations for new targeted therapies. Clin Pharmacol Ther 2009;85:208-11.
6. van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 2009;35:692-706.
7. Brennan M, Williams JA, Chen Y, Tortorici M, Pithavala Y, Liu YC. Meta-analysis of contribution of genetic polymorphisms in drugmetabolizing enzymes or transporters to axitinib pharmacokinetics. Eur J Clin Pharmacol 2012;68:645-55.
8. Hu S, Franke RM, Filipski KK, Hu C, Orwick SJ, de Bruijn EA, et al. Interaction of imatinib with human organic ion carriers. Clin Cancer Res 2008;14:3141-8.
9. Polli JW, Humphreys JE, Harmon KA, Castellino S, O'Mara MJ, Olson KL, et al. The role of efflux and uptake transporters in [N-{3-chloro-4-[(3- fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl] -4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos 2008;36:695-701.
10. Keisner SV, Shah SR. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs 2011;71:443-54.
11. Mandery K, Glaeser H, Fromm MF. Interaction of innovative small molecule drugs used for cancer therapy with drug transporters. Br J Pharmacol 2012;165:345-62.
12. Konig J, Cui Y, Nies AT, Keppler D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 2000;275:23161-8.
13. Ramsey LB, Bruun GH, Yang W, Trevino LR, Vattathil S, Scheet P, et al. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res 2012;22:1-8.
14. de Graan AJ, Lancaster CS, Obaidat A, Hagenbuch B, Elens L, Friberg LE, et al. Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res 2012;18:4433-40.
15. Zimmerman EI, Roberts JL, Li L, Finkelstein D, Gibson AA, Chaudhry AS, et al. Ontogeny and sorafenib metabolism. Clin Cancer Res 2012;18:5788-95.
16. Zaher H, Meyer zu Schwabedissen HE, Tirona RG, Cox ML, Obert LA, Agrawal N, et al. Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. Mol Pharmacol 2008;74:320-9.
17. van de Steeg E, Wagenaar E, van der Kruijssen CM, Burggraaff JE, de Waart DR, Elferink RP, et al. Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. J Clin Invest 2010;120:2942-52.
18. van de Steeg E, Stranecky V, Hartmannova H, Noskova L, Hrebicek M, Wagenaar E, et al. Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J Clin Invest 2012;122:519-28.
19. Emoto C, Yamazaki H, Yamasaki S, Shimada N, Nakajima M, Yokoi T. Characterization of cytochrome P450 enzymes involved in drug oxidations in mouse intestinal microsomes. Xenobiotica 2000;30:943-53.
20. Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 2005;33:434-9.
21. Abe T, Kakyo M, Tokui T, Nakagomi R, Nishio T, Nakai D, et al. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem 1999;274:17159-63.
22. Evers R, Chu XY. Role of the murine organic anion-transporting polypeptide 1b2 (Oatp1b2) in drug disposition and hepatotoxicity. Mol Pharmacol 2008;74:309-11.
23. Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res 2009;15: 6062-9.
24. Lancaster CS, Bruun GH, Peer CJ, Mikkelsen TS, Corydon TJ, Gibson AA, et al. OATP1B1 pPolymorphism as a determinant of erythromycin disposition. Clin Pharmacol Ther 2012;92:642-50.
25. Iusuf D, van de Steeg E, Schinkel AH. Functions of OATP1A and 1B transporters in vivo: insights from mouse models. Trends Pharmacol Sci 2012;33:100-8.
26. Roth M, Obaidat A, Hagenbuch B. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol 2012;165:1260-87.
27. Hagenbuch B, Adler ID, Schmid TE. Molecular cloning and functional characterization of the mouse organic-anion-transporting polypeptide 1 (Oatp1) and mapping of the gene to chromosome X. Biochem J 2000;345:115-20.
28. Jain L, Woo S, Gardner ER, Dahut WL, Kohn EC, Kummar S, et al. Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br J Clin Pharmacol 2011;72:294-305.
29. Hilger RA, Richly H, Grubert M, Kredtke S, Thyssen D, Eberhardt W, et al. Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis. Int J Clin Pharmacol Ther 2009;47:61-4.
30. Picard N, Yee SW, Woillard JB, Lebranchu Y, Le Meur Y, Giacomini KM, et al. The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin Pharmacol Ther 2010;87:100-8.
31. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1.5, SLCO1B1.15 and SLCO1B1.15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 2005;15:513-22.
32. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 2011;63: 157-81.